

Special Issue

The Influence of Epigenetic Regulation on the Tumor Microenvironment: Mechanisms and Therapeutic Implications

Message from the Guest Editor

Epigenetic modifications play a pivotal role in shaping the behavior of cells within the tumor microenvironment (TME), influencing various cellular processes that are crucial for tumor progression and immune evasion. By modulating core gene expression, these modifications can lead to the dysregulation of neoplastic cells, thereby promoting carcinogenesis. One significant impact of epigenetic changes is on the immune cells within the TME, where they can either suppress immunosuppressive cells or activate anti-cancer T effector cells, thus altering the immune landscape of the tumor. Epi-therapeutic strategies have emerged as promising interventions that may offer distinct advantages over traditional therapies such as chemotherapy and radiotherapy, by specifically targeting epigenetic alterations to modulate the TME more effectively. These strategies not only aim to normalize the phenotypes of cells within the TME, but also repress immunosuppressive factors, thereby potentially improving the overall prognosis and therapeutic outcomes for cancer patients.

Guest Editor

Dr. Mariarosaria Conte

Department of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy

Deadline for manuscript submissions

30 September 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/211137

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)